Q3 Biopharma Sentiment Index shows regulatory optimism rising after Marty Makary and Vinay Prasad's FDA exits, though scientists remain pessimistic.
Aramark, Whirlpool, Grainger, Kraft Heinz, Ralph Lauren & Sterling Jewelers sued UnitedHealth for overpaying medical claims, ...
Microsoft’s MAI-DxO diagnosed 83% of complex journal cases vs. 36% for doctors; a Beth Israel triage study starts within ...
WuXi AppTec raises 2026 guidance again as Q3 revenue jumps 38% to $2.5B, despite its fight over the Pentagon’s Chinese military designation ...
Roche will seek European approval for its promising new breast cancer pill giredestrant later than it once expected, ...
Eli Lilly's Jacob Van Naarden leads aggressive dealmaking to offset tirzepatide's patent cliff, with 12+ acquisitions that ...
BioNTech and DualityBio weigh next steps after HER2 ADC trastuzumab pamirtecan posts a modest Phase 3 win in HER2-low breast ...
Aspen, Bambusa eye $135M IPOs; ESMO data on AZ/Takeda ADCs, Hutchmed's Orpathys+Tagrisso, J&J's JNJ-6143, Jazz's Ziihera; ...
Akeso’s ivonescimab posts 14.9-month median OS vs. 12.1 for Imfinzi in China Ph3 biliary tract cancer trial at ESMO.
Pfizer’s failed Seagen ADC sigvotatug vedotin showed a 2.5-month OS edge in second-line NSCLC in a post-hoc ESMO analysis.
MADRID — AstraZeneca said Sunday it might have found a way for patients with mutant non-small cell lung cancer to keep ...
Treasury’s draft outbound investment rules would sharply limit US deals for Chinese drug and biotech assets, opening a 45-day ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results